Trials / Completed
CompletedNCT02999295
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- National Cancer Center, Japan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ramucirumab | Ramucirumab (8 mg/kg) is administered. |
| BIOLOGICAL | Nivolumab | Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered. |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-11-01
- Completion
- 2019-08-01
- First posted
- 2016-12-21
- Last updated
- 2019-08-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02999295. Inclusion in this directory is not an endorsement.